Item Type | Name |
Concept
|
Leukemia
|
Concept
|
Leukemia, B-Cell
|
Concept
|
Leukemia, Radiation-Induced
|
Concept
|
Leukemia, Lymphocytic, Chronic, B-Cell
|
Concept
|
Leukemia, Myeloid
|
Concept
|
Leukemia, Myeloid, Acute
|
Concept
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
Leukemia, Promyelocytic, Acute
|
Concept
|
Leukemia, Myeloid, Chronic-Phase
|
Concept
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
Concept
|
Myeloid-Lymphoid Leukemia Protein
|
Concept
|
Leukemia, Hairy Cell
|
Concept
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
Academic Article
|
Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.
|
Academic Article
|
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
|
Academic Article
|
Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
|
Academic Article
|
Studies of minimal residual disease in acute lymphocytic leukemia.
|
Academic Article
|
CD5+, CD11c+, CD20+ hairy cell leukemia.
|
Academic Article
|
Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?
|
Academic Article
|
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
|
Academic Article
|
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
|
Academic Article
|
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
|
Academic Article
|
Gene expression changes associated with progression and response in chronic myeloid leukemia.
|
Academic Article
|
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
|
Academic Article
|
Progress in the treatment of adults with acute lymphoblastic leukemia.
|
Academic Article
|
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
|
Academic Article
|
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
|
Academic Article
|
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
|
Academic Article
|
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
|
Academic Article
|
Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults.
|
Academic Article
|
Clinical trials in adult AML.
|
Academic Article
|
Pediatric regimens for adult acute lymphoblastic leukemia.
|
Academic Article
|
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
|
Academic Article
|
Preface: acute lymphoblastic leukemia--quo vadis?
|
Academic Article
|
Burkitt lymphoma/leukemia: improving prognosis.
|
Academic Article
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
|
Academic Article
|
Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
|
Academic Article
|
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
|
Academic Article
|
Adult acute lymphoblastic leukemia: concepts and strategies.
|
Academic Article
|
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
|
Academic Article
|
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
|
Academic Article
|
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
|
Academic Article
|
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
|
Academic Article
|
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
|
Academic Article
|
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?
|
Academic Article
|
Children, adolescents, and young adults with leukemia: the empty half of the glass is growing.
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
Academic Article
|
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.
|
Academic Article
|
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
|
Academic Article
|
Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).
|
Academic Article
|
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
|
Academic Article
|
An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.
|
Academic Article
|
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
|
Academic Article
|
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
|
Academic Article
|
Adolescents and young adults with acute lymphoblastic leukemia.
|
Academic Article
|
Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
|
Academic Article
|
Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study.
|
Academic Article
|
Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia.
|
Academic Article
|
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
|
Academic Article
|
Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Listeriosis after 2-chlorodeoxyadenosine treatment.
|
Academic Article
|
Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia.
|
Academic Article
|
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.
|
Academic Article
|
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
|
Academic Article
|
G3139, a BCL-2 antisense oligo-nucleotide, in AML.
|
Academic Article
|
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
|
Academic Article
|
Minimal residual disease: current status in leukemia.
|
Academic Article
|
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
|
Academic Article
|
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
Academic Article
|
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
|
Academic Article
|
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.
|
Academic Article
|
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
|
Academic Article
|
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
|
Academic Article
|
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
|
Academic Article
|
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
|
Academic Article
|
Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies.
|
Academic Article
|
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
|
Academic Article
|
RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia.
|
Academic Article
|
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
|
Academic Article
|
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
|
Academic Article
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
Academic Article
|
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.
|
Academic Article
|
Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.
|
Academic Article
|
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).
|
Academic Article
|
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
|
Academic Article
|
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
|
Academic Article
|
Allogeneic and autologous transplantation for chronic lymphocytic leukemia.
|
Academic Article
|
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
|
Academic Article
|
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
|
Academic Article
|
MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.
|
Academic Article
|
Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
|
Academic Article
|
How I treat acute lymphoblastic leukemia in older adolescents and young adults.
|
Academic Article
|
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.
|
Academic Article
|
Novel drug targets in acute leukemia.
|
Academic Article
|
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
|
Academic Article
|
Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.
|
Academic Article
|
Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).
|
Academic Article
|
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
|
Academic Article
|
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
|
Academic Article
|
Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?
|
Academic Article
|
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.
|
Academic Article
|
Intergroup Trial C10403: A Pediatric Treatment Approach to Improve Outcomes in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
|
Academic Article
|
Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
|
Academic Article
|
Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report.
|
Academic Article
|
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
|
Academic Article
|
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
|
Academic Article
|
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
|
Academic Article
|
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
|
Academic Article
|
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
|
Academic Article
|
Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.
|
Academic Article
|
An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.
|
Academic Article
|
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
|
Academic Article
|
Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).
|
Academic Article
|
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.
|
Academic Article
|
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.
|
Academic Article
|
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
|
Academic Article
|
Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.
|
Academic Article
|
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
|
Academic Article
|
The Persistence of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What?
|
Academic Article
|
High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710).
|
Academic Article
|
A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients (pts) with first relapse of acute myeloid leukemia (AML).
|
Academic Article
|
Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome.
|
Academic Article
|
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
|
Academic Article
|
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.
|
Academic Article
|
Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
|
Academic Article
|
Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc.
|
Academic Article
|
Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.
|
Academic Article
|
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
|
Academic Article
|
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.
|
Academic Article
|
Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach.
|
Academic Article
|
Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole.
|
Academic Article
|
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
|
Academic Article
|
Progress in adult ALL: incorporation of new agents to frontline treatment.
|
Academic Article
|
Treatment of Acute Promyelocytic Leukemia in Adults.
|
Academic Article
|
Should immunologic strategies be incorporated into frontline ALL therapy?
|
Academic Article
|
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
|
Academic Article
|
CD5+ immunophenotype in the bone marrow but not in the peripheral blood in a patient with hairy cell leukemia.
|
Academic Article
|
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
Academic Article
|
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.
|
Academic Article
|
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.
|
Academic Article
|
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.
|
Academic Article
|
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
|
Academic Article
|
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.
|
Academic Article
|
Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
|
Academic Article
|
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.
|
Academic Article
|
Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia.
|
Academic Article
|
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
|
Academic Article
|
Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.
|
Academic Article
|
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.
|
Academic Article
|
Management of acute lymphoblastic leukemia in young adults.
|
Academic Article
|
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
|
Academic Article
|
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
|
Academic Article
|
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
|
Academic Article
|
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
|
Academic Article
|
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
|
Academic Article
|
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
|
Academic Article
|
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
|
Academic Article
|
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
|
Academic Article
|
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.
|
Academic Article
|
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.
|
Academic Article
|
Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
|
Academic Article
|
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance).
|
Academic Article
|
Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
|
Academic Article
|
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
|
Academic Article
|
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
|
Academic Article
|
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
|
Academic Article
|
Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
|
Academic Article
|
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.
|
Academic Article
|
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
|
Academic Article
|
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
|
Academic Article
|
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
|
Academic Article
|
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database.
|
Academic Article
|
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults.
|
Academic Article
|
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
|
Academic Article
|
Thrombosis in ALL: a risk without clear mitigation.
|
Academic Article
|
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
|
Academic Article
|
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
|
Academic Article
|
Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia.
|
Academic Article
|
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
|
Academic Article
|
Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists.
|
Academic Article
|
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
|
Academic Article
|
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
|
Academic Article
|
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.
|
Academic Article
|
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
|
Academic Article
|
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
|
Academic Article
|
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.
|
Academic Article
|
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
|
Academic Article
|
Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
|
Academic Article
|
Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia.
|
Academic Article
|
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
|
Academic Article
|
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
|
Academic Article
|
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).
|
Academic Article
|
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
|
Academic Article
|
The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.
|
Academic Article
|
Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials.
|
Academic Article
|
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.
|
Academic Article
|
SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
|
Academic Article
|
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
|
Academic Article
|
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
|
Academic Article
|
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
|
Academic Article
|
Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia.
|
Academic Article
|
Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.
|
Academic Article
|
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
|
Academic Article
|
MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia.
|
Academic Article
|
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
|
Academic Article
|
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia.
|
Academic Article
|
Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!
|
Academic Article
|
Acute lymphoblastic leukemia displays a distinct highly methylated genome.
|
Academic Article
|
Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia.
|
Academic Article
|
Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia.
|
Academic Article
|
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.
|
Academic Article
|
Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents.
|
Academic Article
|
D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia.
|
Academic Article
|
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
|
Academic Article
|
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.
|
Academic Article
|
Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults.
|
Academic Article
|
Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
|
Academic Article
|
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
|
Academic Article
|
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
|
Academic Article
|
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
|
Academic Article
|
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study.
|
Academic Article
|
CGG-repeat polymorphism of the BCR gene rules out predisposing alleles leading to the Philadelphia chromosome.
|
Academic Article
|
Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma.
|
Academic Article
|
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
|
Academic Article
|
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
|
Academic Article
|
Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.
|
Academic Article
|
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
|
Academic Article
|
Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures.
|
Concept
|
Myeloid Cell Leukemia Sequence 1 Protein
|
Academic Article
|
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T lymphocyte acute lymphoblastic leukemia.
|
Academic Article
|
Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
|
Academic Article
|
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
|
Academic Article
|
Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
|
Academic Article
|
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.
|
Academic Article
|
A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America.
|
Academic Article
|
Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding.
|
Academic Article
|
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
|
Academic Article
|
Therapy of childhood acute lymphoblastic leukemia in resource-poor geospaces.
|
Academic Article
|
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
|
Academic Article
|
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
|
Academic Article
|
Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells.
|
Academic Article
|
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
|
Academic Article
|
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
|
Academic Article
|
Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.
|
Academic Article
|
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
|
Academic Article
|
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
|
Academic Article
|
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
|
Academic Article
|
SINGLE CELL DISSECTION OF DEVELOPMENTAL ORIGINS AND TRANSCRIPTIONAL HETEROGENEITY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
|
Academic Article
|
Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators.
|
Academic Article
|
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
|
Academic Article
|
Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL.
|
Academic Article
|
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
|
Academic Article
|
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
|
Academic Article
|
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
|
Academic Article
|
Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia.
|
Academic Article
|
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia.
|
Academic Article
|
Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.
|
Academic Article
|
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
|
Academic Article
|
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients.
|
Academic Article
|
Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia.
|